{"id":861,"date":"2026-05-25T03:49:51","date_gmt":"2026-05-25T03:49:51","guid":{"rendered":"https:\/\/wuhantopmiraclepeptides.com\/?post_type=product&p=861"},"modified":"2026-07-05T13:06:09","modified_gmt":"2026-07-05T13:06:09","slug":"cjc-1295-mod-grf-1-29-ipamorelin-ghrp-2-blend-9mg","status":"publish","type":"product","link":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/product\/cjc-1295-mod-grf-1-29-ipamorelin-ghrp-2-blend-9mg\/","title":{"rendered":"CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)"},"content":{"rendered":"

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg): A Triple\u2011Pathway Tool for Advanced Growth Hormone Research<\/span><\/h1>\n

If your research delves into the complex neuroendocrine regulation of the growth hormone (GH) axis, the\u00a0<\/span>CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)<\/span><\/strong>\u00a0offers a uniquely comprehensive experimental platform. This 9 mg formulation combines three well\u2011characterised GH secretagogues\u2014<\/span>CJC-1295 (Mod GRF 1-29)<\/span><\/strong>, a modified GHRH analogue;\u00a0<\/span>Ipamorelin<\/span><\/strong>, a selective ghrelin receptor agonist; and\u00a0<\/span>GHRP-2<\/span><\/strong>, a potent growth hormone\u2011releasing peptide\u2014each acting through distinct yet complementary mechanisms at the pituitary and hypothalamic levels.<\/span><\/p>\n

CJC-1295 provides the primary stimulus to initiate GH synthesis by activating the classical GHRH receptor pathway.<\/span>\u00a0Ipamorelin and GHRP-2, meanwhile, engage the ghrelin\/GHS\u2011R1a receptor system through different binding modes.<\/span>\u00a0By simultaneously targeting two major regulatory axes that converge at the pituitary, this blend allows researchers to model the synergistic interplay that governs GH pulsatility, providing deeper insight into the circuits that regulate endocrine signalling, metabolic homeostasis, and tissue repair.<\/span><\/p>\n

At\u00a0<\/span>Wuhan Top Miracle Peptides<\/span><\/strong>, we supply high\u2011purity\u00a0<\/span>CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)<\/span><\/strong>\u00a0to research institutions and wholesale buyers across the\u00a0<\/span>United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA<\/span><\/strong>. Every batch is lyophilised, HPLC\u2011verified to \u226598% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into GH regulation, IGF\u20111 signalling, and metabolic research begin with uncompromising quality.<\/span><\/p>\n

What Is the CJC-1295 & Ipamorelin & GHRP\u20112 Blend and How Does It Work?<\/span><\/h2>\n

To fully appreciate the research potential of the\u00a0<\/span>CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)<\/span><\/strong>, it is essential to understand the distinct yet convergent mechanisms of its three components.<\/span><\/p>\n

CJC-1295 (Mod GRF 1-29): The Stabilised GHRH Analogue<\/span><\/h3>\n

CJC-1295 (Mod GRF 1-29), also referred to as\u00a0<\/span>CJC-1295 without DAC<\/span><\/strong>, is a modified analogue of growth hormone\u2011releasing hormone (GHRH). It is a 29\u2011amino\u2011acid peptide with four amino acid substitutions that enhance its activity and render it resistant to proteolytic degradation.<\/span>\u00a0Unlike CJC\u20111295\u2011DAC, which contains a drug affinity complex and has a half\u2011life of approximately 8 days, Mod GRF 1\u201129 does not contain the DAC moiety and has a shorter half\u2011life.<\/span><\/p>\n

As a GHRH analogue, CJC\u20111295 acts on receptors in the anterior pituitary gland to stimulate the release of human growth hormone in a pulsatile manner.<\/span>\u00a0It has been shown to produce a 4\u2011fold increase in GH area under the curve over a 2\u2011hour period compared with native hGRF(1\u201129).<\/span>\u00a0The version without DAC creates short, sharp GH spikes that more closely mimic natural physiology.<\/span><\/p>\n

Ipamorelin: The Selective Ghrelin Receptor Agonist<\/span><\/h3>\n

Ipamorelin is a synthetic pentapeptide (Aib\u2011His\u2011D\u20112\u2011Nal\u2011D\u2011Phe\u2011Lys\u2011NH\u2082) that was first described in a 1998 paper in the\u00a0<\/span>European Journal of Endocrinology<\/span><\/em>\u00a0as \u201cthe first selective growth hormone secretagogue\u201d.<\/span>\u00a0Its defining pharmacological advantage is GH stimulation\u00a0<\/span>without elevating cortisol, ACTH, or prolactin<\/span><\/strong>, even at doses 200\u2011fold above the GH\u2011release ED\u2085\u2080.<\/span><\/p>\n

Ipamorelin binds to COS\u20117 cells expressing GHS\u2011R1a with a Ki of 63.4 nM.<\/span>\u00a0It stimulates GH release through selective activation of the ghrelin receptor (growth hormone secretagogue receptor, GHS\u2011R1a), inducing intracellular signalling cascades involving calcium mobilisation and protein kinase C.<\/span><\/p>\n

GHRP-2: The Potent Growth Hormone\u2011Releasing Peptide<\/span><\/h3>\n

GHRP-2 (Pralmorelin, KP\u2011102) is a synthetic hexapeptide classified as part of the growth hormone secretagogue family.<\/span>\u00a0It has been widely explored for its strong binding affinity to the ghrelin receptor and its robust GH\u2011releasing activity.<\/span>\u00a0Like GHRP\u20116, it acts through the same receptor and mechanism, stimulating GH release via phospholipase C and intracellular calcium flux.<\/span><\/p>\n

GHRP-2 has been studied for its potential as a diagnostic agent for GH deficiency and its ability to stimulate growth in children.<\/span>\u00a0It also increases food intake in healthy men, consistent with its ghrelin\u2011mimetic properties.<\/span><\/p>\n

Mechanism of Synergy: Triple\u2011Pathway Activation<\/span><\/h3>\n

The scientific rationale for combining CJC\u20111295 (Mod GRF 1\u201129), Ipamorelin, and GHRP\u20112 lies in their convergent yet distinct mechanisms. When conceptualised as a blended research framework, these peptides invite investigation into how complementary properties might interact to yield distinct hormonal output patterns.<\/span><\/p>\n